Ancient footprints from Australia reveal earliest-known reptile
May 14 (Reuters) - Seventeen footprints preserved in a slab of sandstone discovered in southeastern Australia dating to about 355 million years ago are rewriting the history of the evolution of land vertebrates, showing that reptiles arose much earlier than previously known.
The fossilized footprints, apparently made on a muddy ancient river bank, include two trackways plus one isolated print, all displaying hallmark features of reptile tracks including overall shape, toe length and associated claw marks, researchers said. They appear to have been left by a reptile with body dimensions similar to those of a lizard, they said.
The footprints reveal that reptiles existed about 35 million years earlier than previously known, showing that the evolution of land vertebrates occurred more rapidly than had been thought.
"So this is all quite radical stuff," said paleontologist Per Ahlberg of the University of Uppsala in Sweden, who led the study published on Wednesday in the journal Nature, opens new tab.
The Australian footprints were preserved in a sandstone slab measuring about 14 inches (35 cm) across that was found on the banks of the Broken River near the town of Barjarg in the state of Victoria.
The story of land vertebrates started with fish leaving the water, a milestone in the evolution of life on Earth. These animals were the first tetrapods - meaning "four feet" - and they were the forerunners of today's terrestrial vertebrates: amphibians, reptiles, mammals and birds. Footprints in Poland dating to about 390 million years ago represent the oldest fossil evidence for these first tetrapods, which lived an amphibious lifestyle.
These creatures were the ancestors of all later land vertebrates. Their descendants split into two major lineages - one leading to today's amphibians and the other to the amniotes, a group spanning reptiles, mammals and birds. The amniotes, the first vertebrates to lay eggs on land and thus finally break free of the water, cleaved into two lineages, one leading to reptiles and the other to mammals. Birds evolved much later from reptile ancestors.
The Australian footprints each are approximately 1-1.5 inches (3-4 cm) long. They appear to have been left by three individuals of the same reptile species, with no tail drag or body drag marks. No skeletal remains were found but the footprints offer some idea of what the reptile that made them looked like.
"The feet are rather lizard-like in shape, and the distance between hip and shoulder appears to have been about 17 cm (6.7 inches). Of course we don't know anything about the shape of the head, the length of the neck or the length of the tail, but if we imagine lizard-like proportions the total length could have been in the region of 60 cm to 80 cm (24 to 32 inches)," Ahlberg said.
"In terms of its overall appearance, 'lizard-like' is probably the best guess, because lizards are the group of living reptiles that have retained the closest approximation to the ancestral body form," Ahlberg added.
The modest size of the earliest reptiles stands in contrast to some of their later descendants like the dinosaurs.
This reptile probably was a predator because plant-eating did not appear until later in reptilian evolution. The bodies of herbivorous reptiles tend to be big and clunky, whereas this one evidently was lithe with long, slender toes, Ahlberg said.
The researchers also described newly identified fossilized reptile footprints from Poland dating to 327 million years ago that broadly resemble those from Australia. Those also are older than the previous earliest-known evidence for reptiles - skeletal fossils from Canada of a lizard-like creature named Hylonomus dating to around 320 million years ago, as well as fossil footprints from about the same time.
The reptile that left the Australian footprints lived during the Carboniferous Period, a time when global temperatures were similar to today's, with ice at Earth's poles but a warm equatorial region. Australia at the time formed part of the ancient supercontinent Gondwana and lay at the southern edge of the tropics. There were forests, partly composed of giant clubmoss trees.
"The tracks were left near the water's edge of what was probably quite a large river, inhabited by a diversity of big fishes," Ahlberg said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
North Wales Live
30 minutes ago
- North Wales Live
8ft ambush shark 'more common' than thought on Welsh coast
An enigmatic species of shark known to be favour Welsh waters could be more abundant than previous suspected, scientists believe. The Angel shark, a large flat species resembling a stingray, is unique because it has evolved very differently to other types of shark. Previously only reliably spotted around the Canary Islands, catch evidence from Welsh fishermen has shown that Cardigan Bay is also a stronghold for this elusive and vulnerable species. The Welsh population had thought to be shrinking dramatically as a result of habitat damage and bycatch fishing, with one study indicating a 70% decline since 1970. A major conservation project was launched in the hope of saving a species that lingers on the sea floor, half-buried in sand and mud, waiting for prey to swim near them. They can grow up to 2.4m (8ft) long. However a new study, 'People & Nature', from the Zoological Society of London (ZSL) and Natural Resources Wales (NRW) suggests previous Angel shark counts were wide of the mark. Its authors believes changes to commercial fishing practices have seen fewer angel sharks caught. As the speckled, caramel-coloured sharks are masters of camouflage, finding them on the sea floor is virtually impossible. Instead, evidence from boat captains is the only reliable way the population can be assessed. It's now thought fishermen are catching fewer not because numbers are dwindling but because they are targeting different waters and using species-specific nets. To reach its conclusions, the ZSL-led study harnessed the expertise of Welsh fishing organisations. Co-author was Charlie Bartlett, a charter fisherman from Gwynedd, who said: 'I've spent over 50 years working along the Welsh coast, and over the years I've come to know these waters inside out. 'With their large, flat fins, Angel sharks are unlike any other shark we see here - and over the years I've been fortunate to encounter the species a number of times.' In the 40 years to 2020, some 1,642 Angel sharks were reported in Welsh coastal waters. A particular safe haven is in an area south of the Llŷn Peninsula. While they pose very little risk to humans, they have been known to bite when provoked. Literature analysis going back two centuries revealed they have a long maritime heritage in Wales. No fewer than 16 different names were uncovered, including Monkfish, Banjofish, Bafoon, Shovelnose and Devilfish. Its traditional Welsh name is Maelgi (Monkfish). The species has been adopted as the flagship species for marine conservation in Wales. Working with the Welsh Fishermen's Association (Cymdeithas Pysgotwyr) and Angling Cymru Sea Anglers, scientists interviewed 27 fishers about their operations between 1968 and 2019. It became clear modern practices involve fewer interactions with Angel sharks, leading to fewer sightings. Lead author Francesca Mason, a ZSL researcher at the Institute of Zoology's Ocean Predator Lab, said: 'There may be more Angel sharks swimming off the Welsh coast than we previously thought – we're just having a harder time spotting them. 'While this is a good sign if less Angel sharks are being caught accidentally, it also means we now need new ways to monitor them to build a more accurate picture of how these sharks are doing.' Instead of relying on chance sightings, scientists are now pinning their hopes on a novel technique involving environmental DNA (eDNA). This can build up in the shark's surroundings through the shedding of dead skin cells or blood loss from a wound. Already eDNA is being measured for Angel Shark Project: Wales, part of the wider work of Project SIARC (Sharks Inspiring Action and Research with Communities). Jake Davies, technical specialist for Project SIARC, said: 'With their excellent camouflage, one of the hardest challenges we face studying Angel sharks is simply finding them. eDNA allows us to study species without having to spot them. 'By studying eDNA in Cardigan and Carmarthen Bays, we've confirmed the presence of a range of native sharks, skates and rays - including Angel sharks - in these more turbulent waters where other monitoring methods aren't as effective. 'Fishers today may be less likely to come across Angel sharks than they were 50 years ago, but through combining this technique with local knowledge, we can continue building a stronger picture of their status and distribution along the Welsh coast.' The Angel shark work was supported by the On the Edge conservation charity, the National Lottery Heritage Fund, Welsh Government and the Welsh Government's Nature Networks Fund.
Reuters
10 hours ago
- Reuters
Magnitude 6.5 earthquake strikes Colombia, GFZ says
June 8 (Reuters) - A magnitude 6.5 earthquake struck Columbia on Sunday, the German Research Centre for Geosciences (GFZ) said. The quake was at a depth of 10 km (6.21 miles), GPZ said.
Reuters
3 days ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
